Lead Plaintiff Deadline is November 21, 2016

NEW YORK, NY / ACCESSWIRE / September 28, 2016 / Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) in the United States District Court for the Central District of California. The class action is on behalf of a class consisting of all persons or entities who purchased Spectrum securities between December 16, 2015 through September 16, 2016, inclusive (the "Class Period").

Shareholders who have incurred losses in Spectrum Pharmaceuticals, Inc. are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774. You may also review the filed complaint and obtain additional information concerning the action on our website, www.whafh.com.

If you purchased shares of you may, no later than November 21, 2016, request that the Court appoint you lead plaintiff of the proposed class.

The filed Complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Food and Drug Administration (the "FDA") previously questioned whether the data from the 611 and 612 Studies were clinically significant; (2) the FDA instructed defendants in December 2012 not to submit the New Drug Application based on data from the 611 and 612 Studies; and (3) consequently, defendants' public statements regarding the Company's business, operations and prospects were materially false and misleading at all relevant times.

According to the Complaint, on September 16, 2016, TheStreet.com published an article entitled "Spectrum Pharma, FDA and the Buried Truth About a Bladder Cancer Drug Meeting" by Adam Feuerstein. The article disclosed that Spectrum hid from investors a key detail of a meeting with the U.S. Food and Drug Administration ("FDA"), in which regulators told the Company not to seek approval for a bladder cancer drug because two clinical trials failed to benefit patients. The article also describes that a panel of outside experts convened by the FDA reviewed the apaziquone clinical data and decided unanimously the drug did not warrant approval ? and that the FDA would almost certainly follow the panel's recommendation and reject Spectrum's drug.

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein Adler Freeman & Herz LLP by telephone at (800) 575-0735, via e-mail at classmember@whafh.com, or visit our website at www.whafh.com.

## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Patrick Donovan, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: gstone@whafh.com, donovan@whafh.com or classmember@whafh.com
Tel: (800) 575-0735 or (212) 545-4774

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.

SOURCE: Wolf Haldenstein Adler Freeman & Herz LLP